enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Mandibular advancement splint - Wikipedia

   en.wikipedia.org/wiki/Mandibular_advancement_splint

   According to the current American Academy of Sleep Medicine treatment guidelines, [1] oral appliances should be considered for patients with snoring or minor to moderate sleep apnea, or as an alternative to CPAP in non compliant patients with severe obstructive sleep apnea. Where appropriate, they are considered a good therapy choice as they ...

3. Diaphragm pacing - Wikipedia

   en.wikipedia.org/wiki/Diaphragm_pacing

   There are currently three commercially distributed diaphragm pacing devices: Synapse Biomedical, Inc.'s NeuRx (US), Avery Biomedical Devices, Inc.'s Mark IV Breathing Pacemaker (US), [21] and Atrotech OY's Atrostim PNS (Finland). [24] The Synapse and Avery devices are distributed worldwide and approved for use in the United States. [21]

4. Zepbound Weight Loss Medication Approved by FDA to Treat ...

   www.aol.com/fda-approves-weight-loss-medication...

   The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.

5. Snoring - Wikipedia

   en.wikipedia.org/wiki/Snoring

   The pillar procedure is a minimally invasive treatment for snoring and obstructive sleep apnea. In the United States, this procedure was FDA indicated in 2004. During this procedure, three to six+ Dacron (the material used in permanent sutures) strips are inserted into the soft palate, using a modified syringe and local anesthetic.

6. US FDA clears Vivos Therapeutics' oral device for sleep apnea

   www.aol.com/news/us-fda-clears-vivos...

   (Reuters) -Vivos Therapeutics said on Wednesday the U.S. health regulator has cleared its oral device for severe obstructive sleep apnea (OSA), leading a massive rally in the company's shares ...

7. Sleep Apnea Device Maker ResMed Is A Durable MedTech ... - AOL

   www.aol.com/finance/sleep-apnea-device-maker...

   On Thursday, ResMed Inc (NYSE:RMD) reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus of $2.04. The company reported sales of $1.224 billion, up 11% ...